HPRA requests actions from Irish industry

In a letter to the Irish Pharmaceutical Industry Association (IPHA), and its members, the Health Products Regulatory Agency (HPRA) has made a series of requests to mitigate coronavirus-related supply risks to patients.

In the letter, HPRA asks for companies to inform them of:

  • Any anticipated shortages of medicinal products in general or of particular classes of products or therapeutic areas as a result of the current COVID-19 epidemic, either due to disruptions to the supply chain or logistic issues (e.g. transportation, shortage of ancillary supplies)
  • Detailed reason for these anticipated shortages
  • Markets impacted – particular MSs or all EU/EEA
  • Timelines for any anticipated shortages, i.e. extent and duration of the shortage (start and possible duration)
  • Shortage prevention plans developed in the context of the COVID-19 infection, including ability to mitigate the extent or duration and specific challenges they entail”

Information may provided to shortages@hpra.ie.

Read the full letter here.

Tagged with

Published on 19. March 2020 in News, News Ireland